Kh. Hoo et al., INVESTIGATION OF ALPHA(1)-ADRENOCEPTOR SUBTYPES IN CANINE AORTA, USING ALKYLATING-AGENTS, Canadian journal of physiology and pharmacology, 72(1), 1994, pp. 97-103
The ability of putative selective irreversible ligands SZL-49 (1-(4-am
ino-6,7-dimethyoxy-2,5-diene-2-carbonyl) and CEC (chlorethylclonidine)
, for alpha1A and alpha1B adrenoceptor subtypes, respectively, to affe
ct alpha1-adrenoceptors of canine aorta microsomal membranes was inves
tigated. These membranes contain an apparently homogeneous population
of [H-3]prazosin binding sites. SZL-49, like phenoxybenzamine, abolish
ed all binding of [H-3]prazosin. CEC abolished 75% of the prazosin bin
ding sites under the most stringent conditions we applied. However, th
e remaining 25% of binding sites was identical in affinity for prazosi
n with control membranes, and competition studies of other subtype-sel
ective ligands revealed unchanged ability to compete against CEC-sensi
tive and -insensitive sites. We concluded that SZL-49 and CEC are not
alpha1A-and alpha1B-adrenoceptor selective under in vitro conditions.
Our data led to the hypothesis that canine aortic membranes contain ex
clusively alpha1B-adrenoceptors but that current tools for identifying
alpha1-adrenoceptor subtypes proved inadequate in vitro in this study
.